ArticleJournal of the advanced practitioner in oncology2025
Implementation of an Electronic Health Record Alert to Improve Naloxone Coprescribing for Adult Patients With Cancer at Risk for Opioid Overdose.
Article in Journal of the advanced practitioner in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Centers for Disease Control and Prevention and U.S. Public Health Service recommend that clinicians prioritize coprescribing take-home naloxone (THN) for patients with cancer receiving opioids in high doses or in the presence of a concomitant high-risk medication. Despite this, THN coprescribing rates remain low. The aim of this quality improvement project (QIP) was to determine if the implementation of an electronic health record (EHR) alert could result in increased THN coprescribing rates in patients with cancer at risk for opioid overdose. This pre- and post-intervention QIP was conducted in an outpatient medical oncology clinic in the Mountain West region of the US. Opioid prescriptions for the management of cancer-related pain totaling ≥ 100 morphine milligram equivalents (MME) per day or with a concomitant high-risk medication were eligible for inclusion (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.